Ocugen 完成了针对干性年龄相关性黄斑变性地图样萎缩的基因疗法 OCU410 的 1/2 期 ArMaDa 试验的给药。 Ocugen completes dosing for Phase 1/2 ArMaDa trial of gene therapy OCU410 for geographic atrophy in dry age-related macular degeneration.
生物科技公司 Ocugen 宣布完成其 1/2 期 ArMaDa 试验第 2 组的 OCU410 给药，OCU410 是一种针对地图样萎缩（干性年龄相关性黄斑变性晚期）的基因疗法。 Ocugen, a biotech company, announces completion of dosing for cohort 2 of its Phase 1/2 ArMaDa trial for OCU410, a gene therapy targeting geographic atrophy, an advanced stage of dry age-related macular degeneration. OCU410 是一种修饰基因疗法，可能是治疗 GA 的一次性、与基因无关的选择。 OCU410, a modifier gene therapy, may be a one-time, gene-agnostic option for treating GA. 它通过一次视网膜下注射来调节多种疾病途径，包括脂质代谢、炎症、氧化应激和膜攻击复合物。 It regulates multiple disease pathways, including lipid metabolism, inflammation, oxidative stress, and the membrane attack complex, with a single sub-retinal injection.